摘要： In this webinar, we discuss how incorporating modeling and simulation approaches early in development can help reduce late-stage risk by determining feasibility of drugging a given target, prioritizing between targets, or defining optimal drug properties for a target product profile. We also demonstrate how Applied BioMath Assess™ and the Protein Degrader Model Pack can be used to optimize drug properties for protein degrader therapeutics by exploring system characteristics such as binding parameters and the dependence of target expression and turnover on a therapeutic’s degradation profile.

主讲人： Joshuaine Grant, Senior Director, QSP